JUST OUT 3/26 SEEKING " ACAD IS A PRIME ACUQUISTION TARGET" LINKED
Seeking Alpha By: Briam Wilson 3/26/13
Pimavanserin is an inverse agonist of the serotonin receptor 5-HT2A. Molecules working through the same mechanism of action have had limited success so far, which is why pimavanserin in a particularly attractive molecule right now that may pique the interest of other pharmaceutical companies interested in expansion of their psychotic drug pipelines.
This, combined with Acadia's (still) low market capitalization of ~$660 million (at the time of writing) makes
Acadia a prime acquisition target for big pharmaceutical companies, particular those that are struggling with their top-line growth.